Polarizing T and B cell responses by APC-targeted subunit vaccines

Frontiers in Immunology

Volumn 6, Issue JUL, 2015, Pages

  Grødeland, Gunnveig ^a   Fossum, Even ^a   Bogen, Bjarne ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Antibody; APC targeting; Influenza vaccines; T cells; Th1; Th2; Vaccine

Indexed keywords

ANTIGEN; CD11B ANTIGEN; CD40 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; FAS LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HEMAGGLUTININ; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECEPTOR; SERINE PROTEINASE; SIALIDASE; SUBUNIT VACCINE; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; ENDOCYTOSIS; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA VIRUS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; T LYMPHOCYTE; TH2 CELL; VACCINATION;

EID: 84938510703     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00367     Document Type: Article

References (76)

1. Wrigley NG. Electron microscopy of influenza virus. Br Med Bull (1979) 35:35-8.
2. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) (1972) 70:767-77. doi: 10.1017/S0022172400022610
3. Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines (2013) 12:519-36. doi:10.1586/erv.13.35
4. Kilbourne ED, Laver WG, Schulman JL, Webster RG. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol (1968) 2:281-8.
5. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med (1972) 286:1329-32. doi:10.1056/NEJM197206222862502
6. Ogra PL, Chow T, Beutner KR, Rubi E, Strussenberg J, DeMello S, et al. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. J Infect Dis (1977) 135:499-506. doi:10.1093/infdis/135.4.499
7. Wohlbold TJ, Krammer F. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses (2014) 6:2465-94. doi:10.3390/v6062465
8. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med (1999) 5:1157-63. doi:10.1038/13484
9. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol (1990) 64:1375-7.
10. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol (1993) 74(Pt 1):143-6. doi:10.1099/0022-1317-74-1-143
11. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J (2006) 3:102. doi:10.1186/1743-422X-3-102
12. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med (1983) 309:13-7. doi:10.1056/NEJM198307073090103
13. Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine (2015) 33:500-6. doi:10.1016/j.vaccine.2014.11.054
14. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol (2006) 176:6333-9. doi:10.4049/jimmunol.176.10.6333
15. Bender BS, Croghan T, Zhang L, Small PA Jr. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med (1992) 175:1143-5. doi:10.1084/jem.175.4.1143
16. van de Sandt CE, Kreijtz JH, de MG, Geelhoed-Mieras MM, Hillaire ML, Vogelzang-van Trierum SE, et al. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol (2014) 88:1684-93. doi:10.1128/JVI.02843-13
17. Weinfurter JT, Brunner K, Capuano SV III, Li C, Broman KW, Kawaoka Y, et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog (2011) 7:e1002381. doi:10.1371/journal.ppat.1002381
18. Cerwenka A, Morgan TM, Harmsen AG, Dutton RW. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J Exp Med (1999) 189:423-34. doi:10.1084/jem.189.2.423
19. Hamada H, Garcia-Hernandez ML, Reome JB, Misra SK, Strutt TM, McKinstry KK, et al. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol (2009) 182:3469-81. doi:10.4049/jimmunol.0801814
20. Liu CC, Walsh CM, Young JD. Perforin: structure and function. Immunol Today (1995) 16:194-201. doi:10.1016/0167-5699(95)80121-9
21. Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today (1995) 16:202-6. doi:10.1016/0167-5699(95)80122-7
22. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 370:650-2. doi:10.1038/370650a0
23. Topham DJ, Tripp RA, Doherty PC. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol (1997) 159:5197-200.
24. Alam S, Sant AJ. Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J Virol (2011) 85:13310-21. doi:10.1128/JVI.05728-11
25. Topham DJ, Doherty PC. Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells. J Virol (1998) 72:882-5.
26. Pulendran B, Artis D. New paradigms in type 2 immunity. Science (2012) 337:431-5. doi:10.1126/science.1221064
27. Allan W, Tabi Z, Cleary A, Doherty PC. Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. J Immunol (1990) 144:3980-6.
28. Anders EM, Peppard PM, Burns WH, White DO. In vitro antibody response to influenza virus. I. T cell dependence of secondary response to hemagglutinin. J Immunol (1979) 123:1356-61.
29. Riberdy JM, Christensen JP, Branum K, Doherty PC. Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J Virol (2000) 74:9762-5. doi:10.1128/JVI.74.20.9762-9765.2000
30. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med (2012) 18:274-80. doi:10.1038/nm.2612
31. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol (2006) 177:2888-98. doi:10.4049/jimmunol.177.5.2888
32. Kawamura H, Berzofsky JA. Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J Immunol (1986) 136:58-65.
33. Casten LA, Pierce SK. Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures. J Immunol (1988) 140:404-10.
34. Snider DP, Segal DM. Targeted antigen presentation using crosslinked antibody heteroaggregates. J Immunol (1987) 139:1609-16.
35. Baier G, Baier-Bitterlich G, Looney DJ, Altman A. Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro. J Virol (1995) 69:2357-65.
36. Lunde E, Munthe LA, Vabo A, Sandlie I, Bogen B. Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat Biotechnol (1999) 17:670-5. doi:10.1038/10883
37. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 194:769-79. doi:10.1084/jem.194.6.769
38. Fredriksen AB, Sandlie I, Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther (2006) 13:776-85. doi:10.1016/j.ymthe.2005.10.019
39. Grodeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B. DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J Immunol (2013) 191:3221-31. doi:10.4049/jimmunol.1300504
40. Fossum E, Grodeland G, Terhorst D, Tveita AA, Vikse E, Mjaaland S, et al. Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8 T-cell responses against influenza virus. Eur J Immunol (2014) 45(2):624-35. doi:10.1002/eji.201445080
41. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol (1999) 17:253-8. doi:10.1038/6995
42. Grodeland G, Mjaaland S, Tunheim G, Fredriksen AB, Bogen B. The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype. PLoS One (2013) 8:e80008. doi:10.1371/journal.pone.0080008
43. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine (2008) 26:201-14. doi:10.1016/j.vaccine.2007.10.062
44. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 137:1142-62. doi:10.1084/jem.137.5.1142
45. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol (2014) 14:571-8. doi:10.1038/nri3712
46. Nair-Gupta P, Blander JM. An updated view of the intracellular mechanisms regulating cross-presentation. Front Immunol (2013) 4:401. doi:10.3389/fimmu.2013.00401
47. Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8-dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol (2001) 166:5327-30. doi:10.4049/jimmunol.166.9.5327
48. Crozat K, Tamoutounour S, Vu Manh TP, Fossum E, Luche H, Ardouin L, et al. Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8{alpha}+ type. J Immunol (2011) 187:4411-5. doi:10.4049/jimmunol.1101717
49. Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, Guttler S, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity (2009) 31:823-33. doi:10.1016/j.immuni.2009.08.027
50. Terhorst D, Fossum E, Baranska A, Tamoutounour S, Malosse C, Garbani M, et al. Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses. J Immunol (2015) 194(12):5895-902. doi:10.4049/jimmunol.1500564
51. Hartung E, Becker M, Bachem A, Reeg N, Jakel A, Hutloff A, et al. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J Immunol (2015) 194:1069-79. doi:10.4049/jimmunol.1401903
52. Schiavo R, Baatar D, Olkhanud P, Indig FE, Restifo N, Taub D, et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood (2006) 107:4597-605. doi:10.1182/blood-2005-08-3207
53. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol (2007) 178:4169-76. doi:10.4049/jimmunol.178.7.4169
54. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science (1987) 236:944-7. doi:10.1126/science.3107127
55. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 5:520. doi:10.3389/fimmu.2014.00520
56. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 23:41-51. doi:10.1016/j.immuni.2005.05.010
57. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell (2014) 158:1243-53. doi:10.1016/j.cell.2014.08.023
58. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med (2014) 20:143-51. doi:10.1038/nm.3443
59. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol (2001) 115:807-11. doi:10.1046/j.1365-2141.2001.03166.x
60. Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin TJ, Lo JC, et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood (2008) 112:3264-73. doi:10.1182/blood-2008-05-155176
61. Li J, Ahmet F, Sullivan LC, Brooks AG, Kent SJ, De RR, et al. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol (2014) 45(3):854-64. doi:10.1002/eji.201445127
62. Lahoud MH, Ahmet F, Kitsoulis S, Wan SS, Vremec D, Lee CN, et al. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J Immunol (2011) 187:842-50. doi:10.4049/jimmunol.1101176
63. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest (2008) 118:2098-110. doi:10.1172/JCI34584
64. Park HY, Light A, Lahoud MH, Caminschi I, Tarlinton DM, Shortman K. Evolution of B cell responses to Clec9A-targeted antigen. J Immunol (2013) 191:4919-25. doi:10.4049/jimmunol.1301947
65. Reuter A, Panozza SE, Macri C, Dumont C, Li J, Liu H, et al. Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination. J Immunol (2015) 194(6):2696-705. doi:10.4049/jimmunol.1402535
66. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science (2007) 316:612-6. doi:10.1126/science.1137971
67. Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood (2011) 118:4111-9. doi:10.1182/blood-2011-04-346957
68. Carayanniotis G, Barber BH. Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature (1987) 327:59-61. doi:10.1038/327059a0
69. Castro FV, Tutt AL, White AL, Teeling JL, James S, French RR, et al. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol (2008) 38:2263-73. doi:10.1002/eji.200838302
70. White AL, Tutt AL, James S, Wilkinson KA, Castro FV, Dixon SV, et al. Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant. Immunology (2010) 131:141-51. doi:10.1111/j.1365-2567.2010.03285.x
71. Chaplin JW, Chappell CP, Clark EA. Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation, and immunological memory. J Exp Med (2013) 210:2135-46. doi:10.1084/jem.20130188
72. Valentine MA, Clark EA, Shu GL, Norris NA, Ledbetter JA. Antibody to a novel 95-kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. J Immunol (1988) 140:4071-8.
73. Miura Y, Shimazu R, Miyake K, Akashi S, Ogata H, Yamashita Y, et al. RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood (1998) 92:2815-22.
74. Chaplin JW, Kasahara S, Clark EA, Ledbetter JA. Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway. J Immunol (2011) 187:4199-209. doi:10.4049/jimmunol.1100198
75. Yuseff MI, Pierobon P, Reversat A, Lennon-Dumenil AM. How B cells capture, process and present antigens: a crucial role for cell polarity. Nat Rev Immunol (2013) 13:475-86. doi:10.1038/nri3469
76. Batista FD, Iber D, Neuberger MS. B cells acquire antigen from target cells after synapse formation. Nature (2001) 411:489-94. doi:10.1038/35078099